Appendix C – Surveillance Form for Carbapenemase-Producing Organisms (CPO) Identified in Acute Care Facility

_				
1	Unique Identifier – assigned by BCCDC Public Health Laboratory (PHL)			
2	Patient's status ☐ Inpatient ☐ Haemodialysis clinic patient ☐ Other, please specify			
3	Date of admission or visit (dd/mmm/yyyy)			
4	Name of the facility			
5	CPO status ☐ Infection (please also complete appendix D) ☐ Colonization ☐ Unknown			
6	Has the patient had an overnight stay in a hospital or undergone medical/surgical procedure outside of Canada within the past 12 months?			
	☐ Yes, please specify the name of the country ☐ Country not provided			
	□No			
	□ Unknown			
7	Has the patient had haemodialysis outside Canada within the past 12 months?			
	☐ Yes, please specify the name of the country ☐ Country not provided			
	□No			
	☐ Unknown			
0	Was the patient transferred from a unit which was under investigation for CPO transmission?			
8	was the patient dansierred from a diffe which was under investigation for er of dansingsion.			
8	☐ Yes, please specify the name of the unit and facility			
8	·			
δ	☐ Yes, please specify the name of the unit and facility ☐ No - the patient was transferred from a unit or facility which was NOT under investigation for CPO			
8	 Yes, please specify the name of the unit and facility No - the patient was transferred from a unit or facility which was NOT under investigation for CPO transmission □ Unknown - it is unknown whether the unit or facility from which the patient was transferred was 			
9	 Yes, please specify the name of the unit and facility No - the patient was transferred from a unit or facility which was NOT under investigation for CPO transmission Unknown - it is unknown whether the unit or facility from which the patient was transferred was under investigation for CPO transmission 			
	 Yes, please specify the name of the unit and facility No - the patient was transferred from a unit or facility which was NOT under investigation for CPO transmission Unknown - it is unknown whether the unit or facility from which the patient was transferred was under investigation for CPO transmission N/A, the patient was not transferred 			
	 Yes, please specify the name of the unit and facility			
	 Yes, please specify the name of the unit and facility			
	Yes, please specify the name of the unit and facility			
	 Yes, please specify the name of the unit and facility			
	Yes, please specify the name of the unit and facility			
9	☐ Yes, please specify the name of the unit and facility ☐ No - the patient was transferred from a unit or facility which was NOT under investigation for CPO transmission ☐ Unknown - it is unknown whether the unit or facility from which the patient was transferred was under investigation for CPO transmission ☐ N/A, the patient was not transferred Has the patient had contact with a known CPO case within the past 12 months? ☐ Yes, please specify the nature of contact: ☐ Roommate in a healthcare facility ☐ Same unit in a healthcare facility ☐ Household ☐ Other, please specify ☐ No ☐ Unknown			
9	 Yes, please specify the name of the unit and facility			

Once completed, please send it to PICNet at picnet@phsa.ca (cc Guanghong.han@phsa), or fax 604-875-4373

Appendix D – Addendum Form for Carbapenemase-Producing Organisms (CPO) Infections Identified in Acute Care Facility

NB: This form should be complete if a) the case was identified as a CPO infection; b) the case was initially reported as colonization, and subsequently developed into a CPO infection within a year from initial identification. Please ensure that the CPO surveillance form (*Appendix C*) has been completed for this case.

1	Unique Identifier – assigned by BCCDC Public Health Laboratory (PHL)
2	Patients' status ☐ Inpatient ☐ Haemodialysis clinic patient ☐ Other, please specify
3	Date of admission or visit (dd/mmm/yyyy)
4	Name of the facility
5	Date of CPO infection identification (dd/mmm/yyyy)
6	Site(s) of infection ☐ Bloodstream ☐ Urinary tract ☐ Respiratory tract ☐ Wound ☐ Surgical site ☐ Other, please specify
7	Organism(s) isolated (Check all that apply) ☐ Acinetobacter spp. ☐ Serratia spp. ☐ Klebsiella pneumonia ☐ Enterobacter spp. ☐ Escherichia coli ☐ Proteus spp. ☐ Morganella morganii ☐ Citrobacter spp. ☐ Pseudomonas spp. ☐ Other Entero-bacteriaceae, please specify
8	CPO gene(s) detected: NDM KPC OXA-48 VIM IMP SME Other, please specify
9	Was the patient treated with an antibiotic for CPO infection? ☐ Yes, please specify the antibiotic(s) was / were used? (Check all that apply) ☐ Colistin ☐ Tigecycline ☐ Other, please specify ☐ No ☐ Unknown
10	Was ICU admission required due to CPO infections or the complications associated with CPO infection? ☐ Yes – the patient was admitted to ICU as a result of a CPO infection or complications associated with a CPO infection. ☐ No – the patient was not admitted to ICU ☐ N/A – patient was already in ICU due to other medical conditions ☐ Unknown
11	Patient outcome 30 days or up until discharge after identification of CPO infection Patient alive, still in hospital 30 days after diagnosis Patient survived and discharged Patient survived and transferred Patient died

Once completed, please send it to PICNet at picnet@phsa.ca (cc Guanghong.han@phsa) or fax 604-875-4373

Appendix E – Notification of Carbapenemase-Producing Organisms (CPO) Transmission Investigation

Please complete this form for notification of a CPO transmission investigation in your facility or health authority and email to <u>picnet@phsa.ca</u> or fax to 604-875-4373

A. Notification Information					
Health Authority: Fa	acility Name:	Unit:			
Contact Person: Ti	tle:	_			
Contact Phone: Er	mail:	_			
Facility type:	Residential Care Facility	Other ()			
Is this report: Notification of transmission investigation (complete section B below) Notification of transmission investigation resolved (complete section C)					
B. Transmission Investigation Notifica	<u>tion</u>				
Date investigation initiated* (dd/mm/y					
Organism (Genus species)					
CPO gene identified (e.g. NDM, KPC) _					
C. Transmission Investigation Res	<u>solved</u>				
Date investigation closed (dd/mm/yyyy):					
Nahan					
Notes:					
Reported by:	Date:				
. ,					

Once completed, please send it to PICNet at picnet@phsa.ca (cc Guanghong.han@phsa) or fax 604-875-4373

^{*} Date of investigation initiation = date of positive index case. Please contact Dr. Linda Hoang at 604-707-2618 or Linda:Hoang@bccdc.ca for questions or clarifications regarding this form.

Appendix F – Letter to Ordering Provider in Response to CPO Cases Identified in the Community

Date	:		
Dear			
	Health Care Provider (ordering provi	der)	
Re:		,	,
	Patient Last name, First name	PHN	DOB

Public Health has received laboratory notification that your patient tested positive for a carbapenemase-producing organism (CPO) - an emerging public health concern. As per the Public Health Act and the Communicable Disease Regulation, physicians/administrators for laboratories that identify CPO are required to report cases to their local medical health officer.

A provincial non-nominal surveillance program is in place to monitor the epidemiology (e.g. risk factors, laboratory data) of CPO in BC. Each patient isolate is assigned a unique identifier for this purpose. The unique identifier for your patient is ______. Attached is a surveillance form. We ask that you complete this form to the best of your ability and return it by email or fax to the Provincial Infection Control Network of BC at picnet@phsa.ca or 604-875-4373.

CPOs are multi-drug resistant gram negative bacteria that pose significant risk to vulnerable patients in healthcare facilities, as the antibiotics available to treat infections are very limited. Due to this risk, please request that your patient inform any healthcare facility on admission and/or routine healthcare encounters (such as hemodialysis, oncology clinics, BMT day care) that they have tested positive for CPO. Infection Control measures will be put in place to decrease the likelihood of spreading these bacteria to other patients.

At this time, little is known about the carriage and clearance of CPO infections in the community after treatment. Follow-up testing of clearance is not recommended, as carriage may return after treatment with a carbapenem antibiotic.

Interpretation of this laboratory result should be in context of the overall health of your patient. In the community, patients who test positive for a CPO do not generally pose a risk to others. Patients should be advised to maintain good personal hygiene and avoid sharing personal items to prevent spread to others. Added precautions are NOT required in the community office setting.

Attached is a patient information sheet for your patient (CPO Health file). Further information on CPO is available at <u>BCCDC website</u>.

Appendix G – Enhanced Surveillance Form for Carbapenemase-Producing Organisms (CPO) Identified in the Community

1	Unique Identifier – assigned by BCCDC Public Health Laboratory (PHL)		
2	Patient's CPO status ☐ Infection ☐ Colonization ☐ Unknown		
3	Has the patient travelled outside Canada within the past 12 months? Yes, please specify the name of the country Country not provided No Unknown		
4	Has the patient had an overnight stay in a hospital or undergone medical/surgical procedure (e.g., endoscopic procedure, inserting catheter, hemodialysis, outpatient surgery) outside of Canada within the past 12 months? Yes, please specify the name of the country Country not provided No Unknown		
5	Has the patient had an overnight stay or longer in any BC care facilities (e.g., hospital, residential care facility) within the past 12 months? Yes, please specify the name of the facility No Unknown		
6	Has the patient had contact with a known CPO case within the past 12 months? Yes, please specify the nature of contact: Household, i.e., a family member with CPO Non-household, i.e., a friend/acquaintance with CPO Other, please specify		
If the	patient was infected with CPO, please answer the following questions		
7	Site(s) of infection (Check all that apply) ☐ Bloodstream ☐ Urinary tract ☐ Respiratory tract ☐ Wound ☐ Surgical site ☐ Other, please specify		
8	Was the patient treated with an antibiotic for current CPO infection? ☐ Yes, please specify the antibiotic(s) was / were used? (Check all that apply) ☐ Colistin ☐ Tigecycline ☐ Other, please specify		
9	Was the patient admitted to a BC hospital due to current CPO infection? ☐ Yes, the patient was admitted due to CPO infection. Specify the name of the facility		